<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532385</url>
  </required_header>
  <id_info>
    <org_study_id>CUCS-INTEC-MV-TEVE-002</org_study_id>
    <nct_id>NCT04532385</nct_id>
  </id_info>
  <brief_title>Effect of Green Tea Extract on Lipids in Patients With Type 2 Diabetes</brief_title>
  <acronym>HDL</acronym>
  <official_title>Effect of a 12-week Administration of Green Tea Extract on Lipids in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Universitario de Ciencias de la Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Universitario de Ciencias de la Salud, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of this study were to evaluate the effect of a 12-week supplementation&#xD;
      with GTE (400 mg every 12 hours) on serum lipids, arterial stiffness and inflammatory&#xD;
      cytokines in patients with T2DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 12 week randomized double-blind, placebo-controlled trial was conducted in patients with&#xD;
      T2DM to evaluate the effect of green tea extract (sunphenon 90D, TAIYO international,&#xD;
      Minneapolis, US) at a 400 mg/12 hrs dose or calcined magnesia (400 mg/12 hrs) on lipids,&#xD;
      anthropometric variables, arterial stiffness and inflammatory cytokines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2018</start_date>
  <completion_date type="Actual">January 14, 2019</completion_date>
  <primary_completion_date type="Actual">January 14, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>patients were randomly assigned to receive green tea extract (sunphenon 90D, TAIYO international, Minneapolis, US) at a 400 mg/12 hrs dose or calcined magnesia (400 mg/12 hrs).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>An external pharmacy laboratory encapsulated the GTE and placebo, blinded and coded the study treatments.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in cholesterol at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Erba Manheim XL-100 automatic chemistry analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in HDL at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Erba Manheim XL-100 automatic chemistry analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in LDL at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Calculated using Friedewald's equation for LDL (LDL = cholesterol - HDL - triglycerides/5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in triglycerides at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Erba Manheim XL-100 automatic chemistry analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in VLDL at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Calculated using Friedewald's equation for VLDL (VLDL = triglycerides/5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in augmentation index at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Omron HEM-9000AI tonometric system after resting in the sitting position for 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in pulse pressure at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Omron HEM-9000AI tonometric system after resting in the sitting position for 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in central systolic blood pressure at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Omron HEM-9000AI tonometric system after resting in the sitting position for 5 minutes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in IL-6 at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measurement was done using commercially available ELISA kits from Peprotech</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in IL-1β at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measurement was done using commercially available ELISA kits from Peprotech</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in TNF-α at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measurement was done using commercially available ELISA kits from Peprotech</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Erba Manheim XL-100 automatic chemistry analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Hemoglobin A1c at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Bio-Rad Variant Classic Hemoglobin testing system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in systolic blood pressure at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Omron HEM-9000AI tonometric system after resting in the sitting position for 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in diastolic blood pressure at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured using the Omron HEM-9000AI tonometric system after resting in the sitting position for 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IMC at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured with the Tanita TBF-215 Body Composition Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body fat percentage at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured with the Tanita TBF-215 Body Composition Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in fat mass at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured with the Tanita TBF-215 Body Composition Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in lean mass at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured with the Tanita TBF-215 Body Composition Analyzer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body water at week 12</measure>
    <time_frame>baseline and week 12</time_frame>
    <description>Measured with the Tanita TBF-215 Body Composition Analyzer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Dyslipidemias</condition>
  <condition>Arterial Stiffness</condition>
  <arm_group>
    <arm_group_label>GTE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Green tea extract, 400 mg every 12 hours for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Calcined magnesia, 400 mg every 12 hours for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Green tea extract</intervention_name>
    <description>400 mg capsule</description>
    <arm_group_label>GTE</arm_group_label>
    <other_name>Sunphenon 90D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>400 mg capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients with type 2 diabetes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Smoking patients&#xD;
&#xD;
          -  Ischemic heart disease&#xD;
&#xD;
          -  Use of anti-inflammatory or antioxidant drugs&#xD;
&#xD;
          -  Previously diagnosed liver or thyroid disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151. Epub 2017 Dec 8. Review.</citation>
    <PMID>29219149</PMID>
  </reference>
  <reference>
    <citation>Gavish B, Izzo JL Jr. Arterial Stiffness: Going a Step Beyond. Am J Hypertens. 2016 Nov 1;29(11):1223-1233. doi: 10.1093/ajh/hpw061.</citation>
    <PMID>27405964</PMID>
  </reference>
  <reference>
    <citation>Shirwany NA, Zou MH. Arterial stiffness: a brief review. Acta Pharmacol Sin. 2010 Oct;31(10):1267-76. doi: 10.1038/aps.2010.123. Epub 2010 Aug 30. Review.</citation>
    <PMID>20802505</PMID>
  </reference>
  <reference>
    <citation>Lessiani G, Santilli F, Boccatonda A, Iodice P, Liani R, Tripaldi R, Saggini R, Davì G. Arterial stiffness and sedentary lifestyle: Role of oxidative stress. Vascul Pharmacol. 2016 Apr;79:1-5. doi: 10.1016/j.vph.2015.05.017. Epub 2015 Jun 2.</citation>
    <PMID>26044182</PMID>
  </reference>
  <reference>
    <citation>Virdis A, Taddei S. Endothelial Dysfunction in Resistance Arteries of Hypertensive Humans: Old and New Conspirators. J Cardiovasc Pharmacol. 2016 Jun;67(6):451-7. doi: 10.1097/FJC.0000000000000362. Review.</citation>
    <PMID>26808712</PMID>
  </reference>
  <reference>
    <citation>de Maat MP, Pijl H, Kluft C, Princen HM. Consumption of black and green tea had no effect on inflammation, haemostasis and endothelial markers in smoking healthy individuals. Eur J Clin Nutr. 2000 Oct;54(10):757-63.</citation>
    <PMID>11083483</PMID>
  </reference>
  <reference>
    <citation>Stokes GS, Barin ES, Gilfillan KL. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension. Hypertension. 2003 Feb;41(2):297-301.</citation>
    <PMID>12574098</PMID>
  </reference>
  <reference>
    <citation>Vlachopoulos C, Terentes-Printzios D, Ioakeimidis N, Rokkas K, Samentzas A, Aggelis A, Kardara D, Stefanadis C. Beneficial effect of vardenafil on aortic stiffness and wave reflections. J Clin Pharmacol. 2012 Aug;52(8):1215-21. doi: 10.1177/0091270011413586. Epub 2011 Sep 27.</citation>
    <PMID>21953573</PMID>
  </reference>
  <reference>
    <citation>Jeyaseelan L, Rao PS. Methods of determining sample sizes in clinical trials. Indian Pediatr. 1989 Feb;26(2):115-21.</citation>
    <PMID>2753525</PMID>
  </reference>
  <reference>
    <citation>Liu CY, Huang CJ, Huang LH, Chen IJ, Chiu JP, Hsu CH. Effects of green tea extract on insulin resistance and glucagon-like peptide 1 in patients with type 2 diabetes and lipid abnormalities: a randomized, double-blinded, and placebo-controlled trial. PLoS One. 2014 Mar 10;9(3):e91163. doi: 10.1371/journal.pone.0091163. eCollection 2014.</citation>
    <PMID>24614112</PMID>
  </reference>
  <reference>
    <citation>Kohara K, Tabara Y, Oshiumi A, Miyawaki Y, Kobayashi T, Miki T. Radial augmentation index: a useful and easily obtainable parameter for vascular aging. Am J Hypertens. 2005 Jan;18(1 Pt 2):11S-14S.</citation>
    <PMID>15683726</PMID>
  </reference>
  <reference>
    <citation>Cui R, Yamagishi K, Muraki I, Hayama-Terada M, Umesawa M, Imano H, Li Y, Eshak ES, Ohira T, Kiyama M, Okada T, Kitamura A, Tanigawa T, Iso H; CIRCS investigators. Association between markers of arterial stiffness and atrial fibrillation in the Circulatory Risk in Communities Study (CIRCS). Atherosclerosis. 2017 Aug;263:244-248. doi: 10.1016/j.atherosclerosis.2017.06.918. Epub 2017 Jun 22.</citation>
    <PMID>28683363</PMID>
  </reference>
  <reference>
    <citation>Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2008 Jun;27(3):363-70. doi: 10.1016/j.clnu.2008.03.007. Epub 2008 May 12.</citation>
    <PMID>18468736</PMID>
  </reference>
  <reference>
    <citation>Quezada-Fernández P, Trujillo-Quiros J, Pascoe-González S, Trujillo-Rangel WA, Cardona-Müller D, Ramos-Becerra CG, Barocio-Pantoja M, Rodríguez-de la Cerda M, Nérida Sánchez-Rodríguez E, Cardona-Muñóz EG, García-Benavides L, Grover-Páez F. Effect of green tea extract on arterial stiffness, lipid profile and sRAGE in patients with type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled trial. Int J Food Sci Nutr. 2019 Dec;70(8):977-985. doi: 10.1080/09637486.2019.1589430. Epub 2019 May 14.</citation>
    <PMID>31084381</PMID>
  </reference>
  <reference>
    <citation>Brown AL, Lane J, Coverly J, Stocks J, Jackson S, Stephen A, Bluck L, Coward A, Hendrickx H. Effects of dietary supplementation with the green tea polyphenol epigallocatechin-3-gallate on insulin resistance and associated metabolic risk factors: randomized controlled trial. Br J Nutr. 2009 Mar;101(6):886-94. doi: 10.1017/S0007114508047727. Epub 2008 Aug 19.</citation>
    <PMID>18710606</PMID>
  </reference>
  <reference>
    <citation>Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014 Aug;24(8):823-36. doi: 10.1016/j.numecd.2014.01.016. Epub 2014 Jan 31. Review.</citation>
    <PMID>24675010</PMID>
  </reference>
  <reference>
    <citation>Marinovic MP, Morandi AC, Otton R. Green tea catechins alone or in combination alter functional parameters of human neutrophils via suppressing the activation of TLR-4/NFκB p65 signal pathway. Toxicol In Vitro. 2015 Oct;29(7):1766-78. doi: 10.1016/j.tiv.2015.07.014. Epub 2015 Jul 15.</citation>
    <PMID>26187476</PMID>
  </reference>
  <reference>
    <citation>Bogdanski P, Suliburska J, Szulinska M, Stepien M, Pupek-Musialik D, Jablecka A. Green tea extract reduces blood pressure, inflammatory biomarkers, and oxidative stress and improves parameters associated with insulin resistance in obese, hypertensive patients. Nutr Res. 2012 Jun;32(6):421-7. doi: 10.1016/j.nutres.2012.05.007. Epub 2012 Jun 20.</citation>
    <PMID>22749178</PMID>
  </reference>
  <reference>
    <citation>Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut microbiota. Lancet Diabetes Endocrinol. 2015 Mar;3(3):207-15. doi: 10.1016/S2213-8587(14)70134-2. Epub 2014 Jul 22. Review.</citation>
    <PMID>25066177</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Universitario de Ciencias de la Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Fernando Grover Paez</investigator_full_name>
    <investigator_title>Profesor Investigador Titular A</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

